Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CG Oncology, Inc. (CGON)
NASDAQ:CGON
CGON Stock Chart & Stats
Day’s Range― - ―
52-Week Range$25.77 - $48.05
Previous Close$30.46
Volume740.02K
Average Volume (3M)534.08K
Market Cap
$2.15B
Enterprise Value$2.01B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.18
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding76,129,680
10 Day Avg. Volume359,122
30 Day Avg. Volume534,079
Standard Deviation0.11
R-Squared0.15
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2790.22
Price to Cash Flow (P/CF)-29.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.84K
Enterprise Value/Ebitda-21.02
Forecast
1Y Price Target
$68.80Price Target Upside147.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
CG Oncology, Inc. News
PremiumCompany Announcements
CG Oncology Amends Key Executive Employment Agreements
PremiumCompany Announcements
CG Oncology Reports Promising Phase 3 Trial Results---
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyCretostimogene continues to show compelling efficacy, with median duration of response >27 months.
Market PotentialCretostimogene’s profile as a monotherapy is seen as strong enough to secure blockbuster status across multiple NMIBC subsets.
Regulatory AdvancementCG Oncology is anticipated to file for a BLA with their intravesical bladder cancer treatment, cretostimogene, in the BCG-unresponsive NMIBC setting.
Bears Say
Formulation ConcernsThere is caution about whether the subcutaneous formulation of sasanlimab could outperform the combination of cretostimogene and pembrolizumab.
Market BarriersThe ongoing BCG shortages and hesitancy among community urologists to adopt immune-oncology therapies limit the near-term impact of new treatments.
Safety ConcernsThere are concerns about the safety profile of the sasanlimab + BCG combination and what percentage of urologists would be comfortable administering the drug.
---
Ownership Overview
29.42% Insiders
11.07% Mutual Funds
0.03% Other Institutional Investors
48.06% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CGON FAQ
What was CG Oncology, Inc.’s price range in the past 12 months?
CG Oncology, Inc. lowest stock price was $25.77 and its highest was $48.05 in the past 12 months.
What is CG Oncology, Inc.’s market cap?
CG Oncology, Inc.’s market cap is $2.15B.
When is CG Oncology, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CG Oncology, Inc.’s earnings last quarter?
CG Oncology, Inc. released its earnings results on Aug 08, 2024. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.356 by $0.076.
Is CG Oncology, Inc. overvalued?
According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued.
Does CG Oncology, Inc. pay dividends?
CG Oncology, Inc. does not currently pay dividends.
What is CG Oncology, Inc.’s EPS estimate?
CG Oncology, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CG Oncology, Inc. have?
CG Oncology, Inc. has 76,129,680 shares outstanding.
What happened to CG Oncology, Inc.’s price movement after its last earnings report?
CG Oncology, Inc. reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.356. Following the earnings report the stock price went down -6.828%.
Which hedge fund is a major shareholder of CG Oncology, Inc.?
Currently, no hedge funds are holding shares in CGON
---
CG Oncology, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$68.80 (147.04% Upside)
$68.80 (147.04% Upside)
Blogger Sentiment
Neutral
CGON Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Company Description
CG Oncology, Inc.
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life.
---
CGON Stock 12 Month Forecast
Average Price Target
$68.80
▲(147.04% Upside)
Technical Analysis
Best Analysts Covering CGON
1 Year
1 Year Success Rate
0/9 ratings generated profit
1 Year Average Return
-21.04%
reiterated a buy rating last month
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -21.04% per trade.
---